戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ng the efficacy of the drugs dorzolamide and bimatoprost.
2 A nanoparticles, and a therapeutic compound, bimatoprost.
3 patients with OHT or OAG received once-daily bimatoprost 0.01 % for 12 weeks.
4 glaucoma (OAG) or ocular hypertension (OHT), bimatoprost 0.01 % improved tolerability while retaining
5           In the Taiwanese clinical setting, bimatoprost 0.01 % provided significant IOP lowering in
6 rrence and severity of hyperemia produced by bimatoprost 0.01 %, and its efficacy, in the Taiwanese c
7 oprost 0.004% (TRAV) and BAK 0.02%-preserved bimatoprost 0.01% (BIM) during late-day time points in p
8 raocular pressure (IOP)-lowering efficacy of bimatoprost 0.03 %.
9  the study eye; the fellow eye began topical bimatoprost 0.03% once daily.
10 erved PGA monotherapy (latanoprost 0.005% or bimatoprost 0.03%).
11 % ethanol in DMEM) or the free acid forms of bimatoprost (0.01 or 0.1 microg/mL), latanoprost (0.03 o
12      Holter SBP was significantly higher for bimatoprost (135.1 mmHg vs 128.1 mmHg, p=0.04), while no
13 st to least effective drugs were as follows: bimatoprost 5.61 (4.94; 6.29), latanoprost 4.85 (4.24; 5
14     They were randomized to LTFC (8 a.m.) or bimatoprost (8 p.m.) and received 24-hour IOP curve at b
15 nist), Butaprost (EP2 receptor agonist), and Bimatoprost (a prostamide) were compared.
16 ether non-eyelash follicles could respond to bimatoprost, a prostamide F(2alpha) analog recently lice
17  nM) > latanoprost acid (EC(50) = 34.7 nM) > bimatoprost acid (EC(50) = 112 nM) > PGF(2alpha) (EC(50)
18                                  PGF2alphaEA/bimatoprost act via prostaglandin F2alphaFP receptor/FP
19 noprost (isopropyl ester; EC(50) = 778 nM) > bimatoprost (amide; EC(50) = 1410-6940 nM).
20 sent study was to investigate the effects of bimatoprost and a novel prostamide-selective antagonist
21 +/- 0.62 micro M) as well as that induced by bimatoprost and acids of latanoprost and travoprost.
22                        The prostamide analog Bimatoprost and an EP2-selective agonist affects only Cy
23                                              Bimatoprost and latanoprost did not change MMP-2.
24                                              Bimatoprost and latanoprost increased MMP-9 activity by
25                      TIMP-2 was unchanged by bimatoprost and latanoprost, but decreased by unoproston
26 .1+/-10.2 vs 78.2+/-10.1 mmHg (p=0.4) in the bimatoprost and LTFC groups respectively.
27                                              Bimatoprost and LTFC had similar DBPs and OPPs; SBP was
28                     To compare the effect of bimatoprost and the fixed combination latanoprost-timolo
29 ystems were used to test the consequences of bimatoprost and/or AGN 211334 treatment on conventional
30                     Therefore, PGF2alpha and Bimatoprost appear to interact with different receptors
31                                              Bimatoprost, at pharmacologically selective concentratio
32                                              Bimatoprost (BMP), which is a highly effective ocular hy
33                                              Bimatoprost did not lead to a significant reduction in I
34 3T3-L1 or human preadipocytes to PGF2alphaEA/bimatoprost during early differentiation inhibits adipog
35 , defined only at the pharmacological level, Bimatoprost effects on Cyr61 and CTGF were studied in th
36      The present study specifically examines bimatoprost effects on the cells that populate human out
37                                              Bimatoprost effects were insensitive to cholera toxin an
38 OP of -3.2 to -6.4 mmHg was observed for the bimatoprost group compared with -4.2 to -6.4 mmHg for th
39                          Study eyes received bimatoprost implant 10 mug (n = 198) or 15 mug (n = 198)
40 360 degrees SLT procedure in 1 eye and 10-ug bimatoprost implant administration in the contralateral
41                                          The bimatoprost implant demonstrated statistical and clinica
42                                          The bimatoprost implant has potential to improve adherence a
43        Participants (n = 31) received 10-mug bimatoprost implant in the study eye on day 1; IOP (sitt
44  A single intracameral administration of the bimatoprost implant lowered IOP in the habitual position
45                       Both dose strengths of bimatoprost implant met the primary end point of noninfe
46 dothelial cell loss, iritis) was higher with bimatoprost implant than timolol and highest with the 15
47                       Both dose strengths of bimatoprost implant were noninferior to timolol in IOP l
48                                       All 31 bimatoprost implant-treated participants completed the 1
49 asurements were also performed after topical bimatoprost in a separate generation of homozygous FP-kn
50 ll dose strengths were comparable to topical bimatoprost in overall IOP reduction through week 16.
51 ptor gene is critical to the IOP response to bimatoprost in the mouse eye.
52 btained in cell culture experiments in which bimatoprost increased hydraulic conductivity of TM cell
53                                              Bimatoprost increased outflow facility by an average of
54                        The topically applied bimatoprost insert may provide an alternative to daily e
55 le patients were randomized 1:1 to receive a bimatoprost insert plus artificial tears twice daily or
56                   The findings indicate that bimatoprost interacts with a prostamide receptor in the
57 F2alpha ethanolamide (PGF2alphaEA), of which bimatoprost is a potent synthetic analog.
58                                              Bimatoprost is a widely used ocular hypotensive agent to
59 ree acids indicate that latanoprost, but not bimatoprost, is hydrolyzed in the mouse eye after topica
60   Tissue and aqueous humor concentrations of bimatoprost, latanoprost, and their C-1 free acids indic
61 aqueous humor and vitreous concentrations of bimatoprost, latanoprost, and their C-1 free acids were
62                                              Bimatoprost, latanoprost, and travoprost are among the m
63 veness of the prostaglandin analogues (PGAs) bimatoprost, latanoprost, and unoprostone.
64 din F(2 alpha), the ocular hypotensive agent bimatoprost (Lumigan; Allergan, Inc., Irvine, CA) shows
65 n mean IOP was observed over 6 months with a bimatoprost ocular insert and seems to be safe and well
66                                    A topical bimatoprost ocular insert was compared with twice-daily
67 ollicular signaling system and confirms that bimatoprost offers a novel, low-risk therapeutic approac
68                               The effects of bimatoprost on TM and SC cells were inhibited by the pro
69          Adverse events were consistent with bimatoprost or timolol exposure; no unexpected ocular AE
70                    The authors observed that bimatoprost produced an immediate and concentration-depe
71 nately, the precise mechanisms that underlie bimatoprost's distinctive impact on aqueous humor dynami
72 bation with AGN 211334 significantly blunted bimatoprost's effects by 95% or 43%, respectively.
73 treatment with AGN 211334 completely blocked bimatoprost's effects, while coincubation decreased its
74 yelash behavior, and scalp follicles contain bimatoprost-sensitive prostamide receptors in vivo.
75         Taken together, results suggest that bimatoprost specifically activates receptors in both cel
76 as more common with topical bimatoprost than Bimatoprost SR (17.3% vs 6.7% of eyes).
77 glaucoma patients (n = 75) were administered Bimatoprost SR (6 mug, 10 mug, 15 mug, or 20 mug) intrac
78                                              Bimatoprost SR demonstrated favorable efficacy and safet
79                                              Bimatoprost SR provided rapid, sustained IOP lowering.
80 dable bimatoprost sustained-release implant (Bimatoprost SR).
81  regenerative treatments, JAK inhibitors and bimatoprost stimulate repopulation of depleted cells in
82                                        Thus, bimatoprost stimulates human scalp follicles in culture
83 ure (IOP)-lowering effect of a biodegradable bimatoprost sustained-release implant (Bimatoprost SR).
84 ction procedure was more common with topical bimatoprost than Bimatoprost SR (17.3% vs 6.7% of eyes).
85 ug, along with pilocarpine, epinephrine, and bimatoprost that in humans increases the rate of aqueous
86 ficacy and tolerability of fixed-combination bimatoprost/timolol (bim/tim) and dorz/brim/tim in Mexic
87 s, atrial tachycardia and Meniere's disease, bimatoprost to lentigo maligna melanoma, and tafluprost
88                                              Bimatoprost, travoprost, latanoprost, unoprostone isopro
89 ificant reduction in IOP was observed in the bimatoprost-treated eye of wild-type mice at 2 hours, wi
90 plant, respectively, vs 8.4 mm Hg in topical bimatoprost-treated pooled fellow eyes (data censored at
91                           Both PGF2alpha and Bimatoprost up-regulated Cyr61 mRNA expression in the ca
92           Notably, in TM, SC, and CSM cells, bimatoprost was approximately equipotent to the selectiv
93 se to a single 1.2-microg (4 microL) dose of bimatoprost was measured in the treated and untreated fe
94 zed, predominantly involving latanoprost and bimatoprost, with most patients being elderly and female